Japanese pharma firm opens new office in HCM City

Sunday, May 15, 2022 08:31

Japanese pharma firm Eisai Vietnam Co., Ltd opened a new business office in HCM City on Thursday, May 12, 2022. — Photo courtesy of the company

Japan-headquartered pharmaceutical company Eisai Vietnam has inaugurated a new business office in HCM City, reaffirming its decades long presence in the country.

The new office is located at the Saigon Giai Phong Tower at 432-438 Nguyen Thi Minh Khai Street in the city’s District 3.

Yuki Inoue, general director of Eisai Vietnam, said the company aimed to improve the distribution system, introduce innovative drugs, and contribute to improving benefits for patients based on its human health care or “hhc” philosophy.

He explained that Eisai's corporate philosophy gives first thought to patients and their families, and to increasing the healthcare benefits that meet significant unmet medical needs.

Eisai Vietnam is a wholly owned subsidiary of Eisai Co Ltd, a leading global research and development-based pharma company headquartered in Japan.

Founded in 1941 in Tokyo, Japan, Eisai Group Worldwide currently has 46 companies, subsidiaries and more than 10,000 employees worldwide.

Eisai began its business in Viet Nam in the early 1990s through a local agency and opened a representative office in HCM City later.

After oncology, neurology is one of the two focus areas of the group and it has dedicated over 35 years of research and development to find new drugs for dementia.

It had made a major contribution to supporting the prevention and treatment of patients with next-generation dementia, Yuki Inoue said.

A company press release says it is a leader in signing partnerships with companies in the insurance, food and financial sectors to improve the quality of life for dementia patients.

It also contributes to social, environmental and governance initiatives in the country.

On this occasion, Eisai Vietnam also signed a MoU with the Viet Nam Neurological Association for long-term cooperation on increasing access to diagnosis and improving the quality of treatment for the Alzheimer's community by 2025.

They will implement activities to educate and raise awareness of Alzheimer's as well as capacity building in diagnosis, enhancement of medical knowledge and treatment of the disease. — VNS

Comments (0)